Aprea Therapeutics Secures $5.6M Private Placement at Premium, Reports First Partial Response for WEE1 Inhibitor
APRE is trading near its 52-week low of $0.548 (5.9% above the low) on elevated volume (35× avg).
Summary
Aprea Therapeutics announced a $5.6 million private placement, significantly dilutive but priced at a premium to market, to fund operations and R&D, alongside reporting the first unconfirmed partial response in its Phase 1 WEE1 inhibitor study.
Key Events · Financing and Capital Events · APRE
-
Secures $5.6 Million Private Placement
Aprea Therapeutics entered into a securities purchase agreement to sell 6,288,857 shares (or pre-funded warrants) and accompanying common warrants to purchase an equal number of shares, for aggregate gross proceeds of approximately $5.6 million. The combined effective offering price is $0.89 per unit, representing a premium to the current market price.
-
Reports First Unconfirmed Partial Response (uPR) for WEE1 Inhibitor
The company announced the first unconfirmed partial response (uPR) in a patient with PPP2R1A-mutated uterine serous carcinoma (endometrial cancer) in its Phase 1 ACESOT-1051 dose-escalation study of WEE1 inhibitor APR-1051. This patient achieved a 50% reduction in target lesion size and a >90% decrease in CA-125 levels.
-
Amends Prior Financing Agreement
The company amended a Securities Purchase Agreement from December 8, 2025, with requisite holders, to allow for this new private placement, indicating a strategic move to secure additional capital.
-
Financing to Fund Clinical Development
The proceeds from the private placement are intended for general corporate purposes and research and development expenses, specifically to 'proactively backfill patients at key dose levels' in the ongoing APR-1051 study to accelerate dose optimization.
Analysis · APRE · Life Sciences
This filing is critically important for Aprea Therapeutics, a nano-cap company that recently received a Nasdaq deficiency letter. The company announced a $5.6 million private placement, which, while highly dilutive (representing over 100% of its current market capitalization), is priced at a significant premium ($0.89 per unit vs. current stock price of $0.5805). This premium pricing, despite the massive dilution, suggests strong investor confidence in the company's prospects and provides crucial capital for continued operations and R&D. The financing is directly linked to advancing its clinical programs, specifically the WEE1 inhibitor APR-1051, which simultaneously reported its first unconfirmed partial response (uPR) in a Phase 1 study. This early clinical proof-of-concept for APR-1051 is a major positive catalyst for a clinical-stage biopharmaceutical company. The combination of securing vital funding (removing immediate going concern risk) and demonstrating promising clinical efficacy creates a significant positive shift in the company's outlook.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 41.9% of the 327 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APRE was trading at $0.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.1M. The 52-week trading range was $0.55 to $4.65. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.